US5003080A
(en)
*
|
1988-02-22 |
1991-03-26 |
Warner-Lambert Company |
Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
|
AU621874B2
(en)
*
|
1988-02-22 |
1992-03-26 |
Warner-Lambert Company |
Improved process for trans-6-(2-(substituted-pyrrol-1-yl) alkyl)pyran-2-one inhibitors of cholesterol synthesis
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
JP3528186B2
(ja)
*
|
1991-06-24 |
2004-05-17 |
日産化学工業株式会社 |
光学活性キノリンメバロン酸のジアステレオマー塩
|
JP2502605Y2
(ja)
*
|
1992-02-14 |
1996-06-26 |
株式会社大日パレット製作所 |
部品、素材類の取り出し装置
|
SG45369A1
(en)
*
|
1993-01-19 |
1998-10-16 |
Warner Lambert Co |
Stable oral ci-981 formulation and process of preparing same
|
US5298627A
(en)
*
|
1993-03-03 |
1994-03-29 |
Warner-Lambert Company |
Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
|
US5385929A
(en)
*
|
1994-05-04 |
1995-01-31 |
Warner-Lambert Company |
[(Hydroxyphenylamino) carbonyl] pyrroles
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
JP3210552B2
(ja)
*
|
1995-06-07 |
2001-09-17 |
ダイワ精工株式会社 |
魚釣用両軸受型リ−ル
|
NZ286920A
(en)
*
|
1995-07-03 |
1997-06-24 |
Sankyo Co |
Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma
|
SK284202B6
(sk)
*
|
1995-07-17 |
2004-10-05 |
Warner-Lambert Company |
Kryštalické formy I, II a IV atorvastatínu, to je semivápenatej soli kyseliny [R-(R*,R*)]-2-(4-fluórfenyl)-beta,delta-dihydroxy- 5-(1-metyletyl)-3-fenyl-4-(fenylamino)karbonyl]-1H-pyrol-1- heptánovej, alebo jeho hydrátu, farmaceutické kompozície obsahujúce uvedené kryštalické formy a kryštalické formy na použitie ako liečivo
|
HRP960312B1
(en)
*
|
1995-07-17 |
2001-10-31 |
Warner Lambert Co |
NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
|
HRP960313B1
(en)
*
|
1995-07-17 |
2002-08-31 |
Warner Lambert Co |
Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
|
RO120816B1
(ro)
*
|
1995-11-02 |
2006-08-30 |
Warner-Lambert Company |
COMPOZIŢIE FARMACEUTICĂ PE BAZĂ DE INHIBITOR DE ACIL-CoA COLESTEROL O-ACIL-TRANSFERAZEI ŞI INHIBITOR AL REDUCTAZEI HMG-CoA şi UTILIZAREA ACESTEIA
|
US6087511A
(en)
*
|
1996-07-16 |
2000-07-11 |
Warner-Lambert Company |
Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
|
DE19714343A1
(de)
*
|
1997-04-08 |
1998-10-15 |
Bayer Ag |
Chromatographische Enantiomerentrennung von Lactonen
|
GT199800126A
(es)
*
|
1997-08-29 |
2000-01-29 |
|
Terapia de combinacion.
|
GT199800127A
(es)
*
|
1997-08-29 |
2000-02-01 |
|
Combinaciones terapeuticas.
|
US6177121B1
(en)
|
1997-09-29 |
2001-01-23 |
Purdue Research Foundation |
Composition and method for producing low cholesterol eggs
|
US6147109A
(en)
*
|
1997-10-14 |
2000-11-14 |
The General Hospital Corporation |
Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
|
US6083497A
(en)
|
1997-11-05 |
2000-07-04 |
Geltex Pharmaceuticals, Inc. |
Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
|
US20080275104A1
(en)
*
|
1997-11-25 |
2008-11-06 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
US8679534B2
(en)
*
|
1997-12-12 |
2014-03-25 |
Andrx Labs, Llc |
HMG-CoA reductase inhibitor extended release formulation
|
WO1999032434A1
(en)
*
|
1997-12-19 |
1999-07-01 |
Warner-Lambert Export Limited |
Process for the synthesis of 1,3-diols
|
US7223428B2
(en)
*
|
1998-01-09 |
2007-05-29 |
Mars Incorporated |
Method of embossing chocolate products
|
US6180597B1
(en)
|
1998-03-19 |
2001-01-30 |
Brigham And Women's Hospital, Inc. |
Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
|
US6432931B1
(en)
|
1998-06-24 |
2002-08-13 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
US6423751B1
(en)
|
1998-07-14 |
2002-07-23 |
The Brigham And Women's Hospital, Inc. |
Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
|
CN1287769C
(zh)
|
1998-11-20 |
2006-12-06 |
斯凯伊药品加拿大公司 |
可分散的磷脂稳定的微粒
|
SI20109A
(sl)
*
|
1998-12-16 |
2000-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Stabilna farmacevtska formulacija
|
BR9916484A
(pt)
|
1998-12-23 |
2002-01-22 |
Searle Llc |
Combinações de inibidores do transporte de ácido biliar ileal e de agentes sequestrantes de ácido biliar em indicações cardiovasculares
|
JP2002533409A
(ja)
|
1998-12-23 |
2002-10-08 |
ジー.ディー.サール エルエルシー |
心臓血管に適用するためのコレステリルエステル転送タンパク質阻害剤および胆汁酸隔離剤の組み合わせ
|
AU2157400A
(en)
|
1998-12-23 |
2000-07-31 |
G.D. Searle & Co. |
Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
|
NZ512537A
(en)
|
1998-12-23 |
2003-11-28 |
G |
Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
|
CN1338944A
(zh)
|
1998-12-23 |
2002-03-06 |
G.D.瑟尔有限公司 |
用于心血管适应症的胆固醇酯转移蛋白抑制剂和苯氧异丁酸类衍生物的联合形式
|
ATE241386T1
(de)
|
1998-12-23 |
2003-06-15 |
Searle Llc |
Kombinationen von ileumgallensäuretransports inhibitoren und cholesteryl ester transfer protein inhibitoren
|
ES2201822T3
(es)
|
1998-12-23 |
2004-03-16 |
G.D. Searle Llc |
Combinaciones de inhibididores de la proteina de transferencia de ester de colesterilo y de derivados de acido nicotinico para indicaciones cardiovasculares.
|
AU764048B2
(en)
*
|
1999-03-08 |
2003-08-07 |
Merck & Co., Inc. |
Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
|
US6569461B1
(en)
*
|
1999-03-08 |
2003-05-27 |
Merck & Co., Inc. |
Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
|
IN191236B
(de)
*
|
1999-05-25 |
2003-10-11 |
Ranbaxy Lab Ltd |
|
DK1180102T3
(da)
|
1999-05-27 |
2004-09-06 |
Pfizer Prod Inc |
Gensidige prodrugs af amlodipin og atorvastatin
|
HN2000000050A
(es)
|
1999-05-27 |
2001-02-02 |
Pfizer Prod Inc |
Sal mutua de amlodipino y atorvastatina
|
SE9903028D0
(sv)
*
|
1999-08-27 |
1999-08-27 |
Astra Ab |
New use
|
MXPA02001694A
(es)
*
|
1999-08-30 |
2002-08-06 |
Aventis Pharma Gmbh |
Uso de inhibidores del sistema renina-angiotensina en la prevencion de eventos cardiovasculares.
|
HU226640B1
(en)
*
|
1999-10-18 |
2009-05-28 |
Egis Gyogyszergyar Nyilvanosan |
Process for producing amorphous atorvastatin calcium salt
|
US6646133B1
(en)
|
2000-10-17 |
2003-11-11 |
Egis Gyogyszergyar Rt. |
Process for the preparation of amorphous atorvastatin calcium
|
US20040063969A1
(en)
*
|
1999-10-18 |
2004-04-01 |
Egis Gyogyszergyar Rt. |
Process for the preparation of amorphous atorvastatin calcium
|
US20020107173A1
(en)
*
|
1999-11-04 |
2002-08-08 |
Lawrence Friedhoff |
Method of treating amyloid beta precursor disorders
|
JP2003523948A
(ja)
*
|
1999-11-04 |
2003-08-12 |
アンドルクス コーポレーション |
アミロイドβ前駆体障害の治療法
|
CA2392096C
(en)
*
|
1999-11-17 |
2008-07-15 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
US7411075B1
(en)
|
2000-11-16 |
2008-08-12 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
SI20425A
(sl)
*
|
1999-12-10 |
2001-06-30 |
LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. |
Priprava amorfnega atorvastatina
|
AU780247B2
(en)
|
1999-12-17 |
2005-03-10 |
Pfizer Science And Technology Ireland Limited |
A process for producing crystalline atorvastatin calcium
|
EP1237865B1
(de)
|
1999-12-17 |
2005-11-16 |
Pfizer Science and Technology Ireland Limited |
Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form
|
DE60138535D1
(de)
|
2000-02-04 |
2009-06-10 |
Children S Hospital Res Founda |
Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
|
US20040092574A1
(en)
*
|
2000-02-07 |
2004-05-13 |
Bisgaier Charles Larry |
Statin-Lp(a) inhibitor combinations
|
EP1275388A4
(de)
*
|
2000-02-10 |
2003-11-26 |
Takeda Chemical Industries Ltd |
Tnf-alpha inhibitoren
|
GB0003305D0
(en)
|
2000-02-15 |
2000-04-05 |
Zeneca Ltd |
Pyrimidine derivatives
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
JP2003528830A
(ja)
|
2000-03-10 |
2003-09-30 |
ファルマシア・コーポレーション |
テトラヒドロベンゾチエピン類の製造方法
|
USRE44578E1
(en)
|
2000-04-10 |
2013-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
|
ATE524163T1
(de)
|
2000-04-10 |
2011-09-15 |
Teva Pharma |
Stabile pharmazeutische zusammensetzungen enthaltend 7-substituierte-3,5- dihydroxyheptansäuren oder 7-substituierte-3,5- dihydroxyheptensäuren
|
WO2003079972A2
(en)
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
US6534540B2
(en)
|
2000-10-06 |
2003-03-18 |
George Kindness |
Combination and method of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
US20030162829A1
(en)
*
|
2000-10-06 |
2003-08-28 |
George Kindness |
Combination of treatment of cancer utilizing a COX-2 inhibitor and a 3-hydroxy-3-methylglutaryl-coenzyme-a (HMG-CoA) reductase inhibitor
|
PL361097A1
(en)
*
|
2000-10-12 |
2004-09-20 |
Nissan Chemical Industries, Ltd. |
Preventives and remedies for complications of diabetes
|
MXPA03003900A
(es)
|
2000-11-03 |
2005-02-17 |
Teva Pharma |
Forma vii de hemicalcio de atorvastatina.
|
GB0027410D0
(en)
*
|
2000-11-09 |
2000-12-27 |
Pfizer Ltd |
Mutual prodrug of amlodipine and atorvastatin
|
US6737430B2
(en)
|
2000-11-09 |
2004-05-18 |
Pfizer, Inc. |
Mutual prodrug of amlodipine and atorvastatin
|
US6777552B2
(en)
*
|
2001-08-16 |
2004-08-17 |
Teva Pharmaceutical Industries, Ltd. |
Processes for preparing calcium salt forms of statins
|
EP1341785B1
(de)
*
|
2000-11-16 |
2008-10-08 |
Teva Pharmaceutical Industries Ltd. |
Hydrolyse von [r(r*,r*)]-2-(4-fluorphenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-heptansäureestern mit calciumhydroxid
|
US7501450B2
(en)
*
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
IL156055A0
(en)
*
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
LT5196B
(lt)
|
2000-11-30 |
2005-02-25 |
Teva Pharmaceutical Industries Ltd. |
Naujos atorvastatino pusiau kalcio kristalinės formos ir jų gavimo būdai, taip pat ir nauji kitų formų gavimo būdai
|
AU2002224952B2
(en)
*
|
2000-12-27 |
2007-04-05 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of atorvastatin
|
US6476235B2
(en)
*
|
2001-01-09 |
2002-11-05 |
Warner-Lambert Company |
Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
|
EP1734034A3
(de)
|
2001-01-09 |
2007-01-03 |
Warner-Lambert Company LLC |
Carbonsäuresalze von beta-Alaninestern oder -Amiden
|
WO2002057229A1
(en)
|
2001-01-19 |
2002-07-25 |
Biocon India Limited |
FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
|
SI20814A
(sl)
|
2001-01-23 |
2002-08-31 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Priprava amorfnega atorvastatina
|
SI20848A
(sl)
*
|
2001-03-14 |
2002-10-31 |
Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. |
Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
|
US6645946B1
(en)
|
2001-03-27 |
2003-11-11 |
Pro-Pharmaceuticals, Inc. |
Delivery of a therapeutic agent in a formulation for reduced toxicity
|
WO2002083066A2
(en)
|
2001-04-11 |
2002-10-24 |
Bristol-Myers Squibb Company |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
IN190564B
(de)
*
|
2001-04-11 |
2003-08-09 |
Cadila Heathcare Ltd |
|
CN1509180A
(zh)
|
2001-04-18 |
2004-06-30 |
ԭ���ø� |
用脂肪族聚胺治疗综合症x的方法
|
HUP0400381A2
(hu)
|
2001-06-29 |
2004-09-28 |
Warner-Lambert Company Llc |
[R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái
|
JP2004533482A
(ja)
*
|
2001-07-06 |
2004-11-04 |
テバ ファーマシューティカル インダストリーズ リミティド |
6−シアノ−syn−3,5−ジヒドロキシ・ヘキサン酸誘導体による7−アミノ−syn−3,5−ジヒドロキシ・ヘプタン酸誘導体の製法
|
US20040092565A1
(en)
*
|
2001-07-25 |
2004-05-13 |
George Kindness |
Composition and method of sustaining chemotherapeutic effect while reducing dose of chemotherapeutic agent using cox-2 inhibitor and statin
|
US7074818B2
(en)
*
|
2001-07-30 |
2006-07-11 |
Dr. Reddy's Laboratories Limited |
Crystalline forms VI and VII of Atorvastatin calcium
|
PE20030324A1
(es)
*
|
2001-07-31 |
2003-04-03 |
Warner Lambert Co |
Composiciones farmaceuticas de amlodipina y atorvastatina
|
KR20010099097A
(ko)
*
|
2001-08-29 |
2001-11-09 |
강태구 |
베개와 베개용 높이조절패드의 제조방법.
|
EP1572638A4
(de)
*
|
2001-08-31 |
2010-05-05 |
Morepen Lab Ltd |
Verbessertes verfahren zur herstellung von amorphem atorvastatin-calciumsalz (2:1)
|
GB0121436D0
(en)
*
|
2001-09-04 |
2001-10-24 |
Pfizer Ltd |
Biomodulated multiparticulate formulations
|
JP2005532982A
(ja)
*
|
2001-09-24 |
2005-11-04 |
バイエル・フアーマシユーチカルズ・コーポレーシヨン |
肥満の処置のためのピロール誘導体の製造及び使用
|
US6924311B2
(en)
|
2001-10-17 |
2005-08-02 |
X-Ceptor Therapeutics, Inc. |
Methods for affecting various diseases utilizing LXR compounds
|
CN1630709A
(zh)
*
|
2001-10-18 |
2005-06-22 |
百时美施贵宝公司 |
人胰高血糖素样多肽-1模拟物和它们在治疗糖尿病和相关状况中的应用
|
US7238671B2
(en)
*
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
US6806381B2
(en)
*
|
2001-11-02 |
2004-10-19 |
Bristol-Myers Squibb Company |
Process for the preparation of aniline-derived thyroid receptor ligands
|
BR0213501A
(pt)
|
2001-11-02 |
2004-08-24 |
Searle Llc |
Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
|
US6984645B2
(en)
*
|
2001-11-16 |
2006-01-10 |
Bristol-Myers Squibb Company |
Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
|
CA2412012C
(en)
*
|
2001-11-20 |
2011-08-02 |
Ed. Geistlich Soehne Ag Fuer Chemische Industrie |
Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
|
US20060020137A1
(en)
*
|
2001-11-29 |
2006-01-26 |
Limor Tessler |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
US6831102B2
(en)
*
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
UA77990C2
(en)
*
|
2001-12-12 |
2007-02-15 |
|
Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
|
WO2003059884A1
(en)
|
2001-12-21 |
2003-07-24 |
X-Ceptor Therapeutics, Inc. |
Modulators of lxr
|
AU2002367060A1
(en)
*
|
2001-12-21 |
2003-07-30 |
X-Ceptor Therapeutics, Inc. |
Heterocyclic modulators of nuclear receptors
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
JP2005521653A
(ja)
|
2002-01-17 |
2005-07-21 |
ファルマシア コーポレイション |
先端ナトリウム同時依存性胆汁酸輸送(asbt)およびタウロコール酸塩取込みの阻害剤としての新規アルキル/アリールヒドロキシまたはケトチエピン化合物
|
CZ296967B6
(cs)
*
|
2002-02-01 |
2006-08-16 |
Zentiva, A.S. |
Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
|
KR20090045419A
(ko)
*
|
2002-02-19 |
2009-05-07 |
테바 파마슈티컬 인더스트리즈 리미티드 |
아토르바스타틴 헤미-칼슘 용매화합물의 탈용매화
|
GB0204129D0
(en)
*
|
2002-02-21 |
2002-04-10 |
Novartis Ag |
Process for the manufacture of organic compounds
|
KR100379075B1
(en)
*
|
2002-03-07 |
2003-04-08 |
Jinis Biopharmaceuticals Co |
Method for producing low cholesterol animal food product and food product therefrom
|
AU2002247944B2
(en)
*
|
2002-03-18 |
2009-05-21 |
Biocon Limited |
Amorphous Hmg-CoA reductase inhibitors of desired particle size
|
DE10212492B4
(de)
*
|
2002-03-21 |
2012-02-02 |
Daimler Ag |
Kolbenpumpe
|
EP1496982A4
(de)
*
|
2002-04-16 |
2006-07-19 |
Merck & Co Inc |
Feste formen von salzen mit tyrosinkinase-wirkung
|
ITMI20020907A1
(it)
*
|
2002-04-29 |
2003-10-29 |
Chemi Spa |
Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
|
WO2003094845A2
(en)
|
2002-05-08 |
2003-11-20 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
ES2685697T3
(es)
|
2002-05-09 |
2018-10-10 |
The Brigham And Women's Hospital, Inc. |
1L1RL-1 como un marcador de enfermedades cardiovasculares
|
EP1504525A2
(de)
*
|
2002-05-14 |
2005-02-09 |
Siemens Aktiengesellschaft |
Verfahren zum erzeugen eines sendesignals
|
US7057046B2
(en)
*
|
2002-05-20 |
2006-06-06 |
Bristol-Myers Squibb Company |
Lactam glycogen phosphorylase inhibitors and method of use
|
ATE409476T1
(de)
*
|
2002-06-13 |
2008-10-15 |
Novartis Pharma Gmbh |
Calciumsalze von statinen aus indol
|
US20060211761A1
(en)
*
|
2002-07-08 |
2006-09-21 |
Yatendra Kumar |
Hmg-coa-reductase inhibitors
|
US7078430B2
(en)
*
|
2002-07-08 |
2006-07-18 |
Ranbaxy Laboratories Limited |
HMG CoA-reductase inhibitors
|
US20050182106A1
(en)
*
|
2002-07-11 |
2005-08-18 |
Sankyo Company, Limited |
Medicinal composition for mitigating blood lipid or lowering blood homocysteine
|
JP2006506464A
(ja)
*
|
2002-07-23 |
2006-02-23 |
ニュートリノヴァ ニュートリション スペシャリティーズ アンド フード イングリーディエンツ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
食事性繊維およびコレステロール低下物質で造られたコレステロール低下剤
|
CN100357289C
(zh)
*
|
2002-08-06 |
2007-12-26 |
沃尼尔·朗伯有限责任公司 |
制备5-(4-氟苯基)-1-[2-((2r,4r)-4-羟基-6-氧代-四氢-吡喃-2-基)乙基]-2-异丙基-4-苯基-1h-吡咯-3-羧酸苯基酰胺的方法
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
EP1562583A1
(de)
*
|
2002-09-03 |
2005-08-17 |
Morepen Laboratories Ltd. |
Atorvastatin kalzium form vi oder dessen hydrate
|
US20040132728A1
(en)
*
|
2002-09-17 |
2004-07-08 |
Pfizer Inc |
Combinations of atorvastatin and alpha1adrenergic receptor antagonists
|
US20080293750A1
(en)
*
|
2002-10-17 |
2008-11-27 |
Anna Helgadottir |
Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
|
US20060019269A1
(en)
*
|
2002-10-17 |
2006-01-26 |
Decode Genetics, Inc. |
Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
|
DE60332856D1
(de)
*
|
2002-10-23 |
2010-07-15 |
Bristol Myers Squibb Co |
Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
|
EP1562555A2
(de)
*
|
2002-10-24 |
2005-08-17 |
Enos Pharmaceuticals, Inc. |
L-arginin-formulierungen mit verzögerterfreisetzung und herstellungs- und verwendungsverfahren dafür
|
US7098235B2
(en)
|
2002-11-14 |
2006-08-29 |
Bristol-Myers Squibb Co. |
Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
|
US20040102511A1
(en)
*
|
2002-11-21 |
2004-05-27 |
Jitendra Sattigeri |
Substituted pyrrole derivatives
|
EP1424324A1
(de)
*
|
2002-11-28 |
2004-06-02 |
Teva Pharmaceutical Industries Limited |
Kristalline Form F von Atorvastatin
|
US20040110241A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Segal Mark S. |
Materials and methods for monitoring vascular endothelial function
|
CA2510319A1
(en)
*
|
2002-12-20 |
2004-07-15 |
Thomas J. Smith |
High pressure compaction for pharmaceutical formulations
|
US20040132771A1
(en)
*
|
2002-12-20 |
2004-07-08 |
Pfizer Inc |
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
|
BR0317521A
(pt)
|
2002-12-20 |
2005-11-16 |
Pfizer Prod Inc |
Formas de dosagem compreendendo um inibidor da cetp e um inibidor da redutase hmg-coa
|
DE10261067A1
(de)
*
|
2002-12-24 |
2004-08-05 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
|
DE10261061A1
(de)
*
|
2002-12-24 |
2004-07-15 |
Nutrinova Nutrition Specialties & Food Ingredients Gmbh |
Diätetisches Lebensmittel zur positiven Beeinflussung der kardiovaskulären Gesundheit
|
WO2004066929A2
(en)
*
|
2003-01-24 |
2004-08-12 |
Bristol-Myers Squibb Company |
Cycloalkyl containing anilide ligands for the thyroid receptor
|
TW200504021A
(en)
*
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
WO2004082675A1
(en)
*
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
|
SI1603553T1
(sl)
*
|
2003-03-17 |
2012-03-30 |
Japan Tobacco Inc |
Farmacevtski sestavki CETP inhibitorjev
|
US20040254238A1
(en)
*
|
2003-04-07 |
2004-12-16 |
Osteoscreen |
Bone growth stimulation with NO/statin and other NO modulating combinations
|
RS20050760A
(sr)
*
|
2003-04-14 |
2008-04-04 |
Warner-Lambert Company Llc., |
Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline
|
AU2003901812A0
(en)
*
|
2003-04-15 |
2003-05-01 |
Vital Health Sciences Pty Ltd |
Phosphates of secondary alcohols
|
US7557143B2
(en)
*
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
EP1621210B1
(de)
*
|
2003-04-28 |
2013-06-19 |
Daiichi Sankyo Company, Limited |
Mittel zur verstärkung der adiponectin-produktion
|
US7772272B2
(en)
*
|
2003-04-28 |
2010-08-10 |
Daiichi Sankyo Company, Limited |
Method for enhancing glucose uptake into warm-blooded animal adipocytes
|
TWI494102B
(zh)
*
|
2003-05-02 |
2015-08-01 |
Japan Tobacco Inc |
包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
|
AR041089A1
(es)
|
2003-05-15 |
2005-05-04 |
Merck & Co Inc |
Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
|
EP1626713A2
(de)
*
|
2003-05-16 |
2006-02-22 |
Ambit Biosciences Corporation |
Heterocyclische verbindungen und ihre verwendungen
|
US20050182125A1
(en)
*
|
2003-05-16 |
2005-08-18 |
Ambit Biosciences Corporation |
Pyrrole compounds and uses thereof
|
US20040248972A1
(en)
*
|
2003-05-16 |
2004-12-09 |
Ambit Biosciences Corporation |
Compounds and uses thereof
|
CA2527731A1
(en)
*
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives as hmg-coa reductase inhibitors
|
BRPI0410840A
(pt)
|
2003-05-30 |
2006-07-04 |
Ranbaxy Lab Ltd |
derivados substituìdos de pirrol, composição farmacêutica contendo os mesmos e processo para sua preparação
|
US20040242670A1
(en)
*
|
2003-06-02 |
2004-12-02 |
Sonny Sebastian |
Process for preparation of amorphous atorvastatin calcium
|
US7790197B2
(en)
*
|
2003-06-09 |
2010-09-07 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of atorvastatin
|
US7459474B2
(en)
*
|
2003-06-11 |
2008-12-02 |
Bristol-Myers Squibb Company |
Modulators of the glucocorticoid receptor and method
|
US20040253305A1
(en)
*
|
2003-06-12 |
2004-12-16 |
Luner Paul E. |
Pharmaceutical compositions of atorvastatin
|
US20050271717A1
(en)
*
|
2003-06-12 |
2005-12-08 |
Alfred Berchielli |
Pharmaceutical compositions of atorvastatin
|
US7655692B2
(en)
*
|
2003-06-12 |
2010-02-02 |
Pfizer Inc. |
Process for forming amorphous atorvastatin
|
CN1838942A
(zh)
*
|
2003-07-11 |
2006-09-27 |
普罗医药公司 |
递送疏水性药物的组合物和方法
|
EP1648866A1
(de)
|
2003-07-25 |
2006-04-26 |
Avecia Pharmaceuticals Limited |
Verfahren und zwischenprodukte, die sich für die herstellung von statinen, insbesondere atorvastatin, eignen
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
AU2003263581A1
(en)
*
|
2003-08-12 |
2005-02-25 |
Biocon Limited |
Novel antihypercholesterolemic compound
|
JP4553899B2
(ja)
|
2003-08-21 |
2010-09-29 |
メルク フロスト カナダ リミテツド |
カテプシンシステインプロテアーゼ阻害剤
|
EP1510208A1
(de)
*
|
2003-08-22 |
2005-03-02 |
Fournier Laboratories Ireland Limited |
Metformin-Statin-Kombination enthaltende pharmazeutische Zusammensetzungen
|
US20050053664A1
(en)
*
|
2003-09-08 |
2005-03-10 |
Eliezer Zomer |
Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
|
CA2539158A1
(en)
*
|
2003-09-17 |
2005-03-24 |
Warner-Lambert Company Llc |
Crystalline forms of ['r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
|
US20050171207A1
(en)
*
|
2003-09-26 |
2005-08-04 |
Myriad Genetics, Incorporated |
Method and composition for combination treatment of neurodegenerative disorders
|
AU2004279298B2
(en)
*
|
2003-09-29 |
2009-01-29 |
Palmetto Pharmaceuticals, Llc |
Sustained release L-arginine formulations and methods of manufacture and use
|
AU2003272082A1
(en)
*
|
2003-10-07 |
2005-04-21 |
Biocon Limited |
Process for the production of atorvastatin calcium
|
AU2003278597A1
(en)
*
|
2003-11-03 |
2005-05-19 |
Biocon Limited |
(r-(r*,r*))-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-((1-methylethyl) -3-phenyl-4-((phenylamino) carbonyl)- 1h-pyrrole-1-heptanoic acid iron salt
|
JP4839221B2
(ja)
*
|
2003-11-07 |
2011-12-21 |
ジェイ ジェイ ファーマ,インコーポレイテッド |
Hdlを高める併用療法用複合物
|
US7317109B2
(en)
*
|
2003-11-12 |
2008-01-08 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
US7576121B2
(en)
*
|
2003-11-12 |
2009-08-18 |
Phenomix Corporation |
Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
PL1689757T3
(pl)
|
2003-11-12 |
2015-05-29 |
Sino Med Int Alliance Inc |
Heterocykliczne związki kwasu boronowego
|
US7767828B2
(en)
*
|
2003-11-12 |
2010-08-03 |
Phenomix Corporation |
Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
CN1882327A
(zh)
|
2003-11-19 |
2006-12-20 |
症变治疗公司 |
含磷的新的拟甲状腺素药
|
EP1722780A4
(de)
*
|
2003-11-26 |
2008-12-17 |
Univ Duke |
Verfahren zur prävention oder behandlung von glaukom
|
EP1691803A1
(de)
*
|
2003-12-05 |
2006-08-23 |
Warner-Lambert Company LLC |
N-alkyl-pyrrole als hmg-coa-reductase-hemmer
|
CN1913892A
(zh)
*
|
2003-12-17 |
2007-02-14 |
大日本住友制药株式会社 |
药物组合物及联合药物
|
JP2007516287A
(ja)
|
2003-12-23 |
2007-06-21 |
メルク エンド カムパニー インコーポレーテッド |
抗高コレステロール血症化合物
|
US20070161700A1
(en)
*
|
2004-12-28 |
2007-07-12 |
Kowa Company, Ltd. |
Inhibitor for the formation of y-secretase complex
|
CA2456430A1
(en)
*
|
2004-01-28 |
2005-07-28 |
Brantford Chemicals Inc. |
Improved process for the preparation of amorphous atorvastatin calcium
|
WO2005073187A1
(en)
*
|
2004-01-28 |
2005-08-11 |
Apotex Pharmachem Inc. |
Improved process for the preparation of amorphous atorvastatin calcium
|
US8158362B2
(en)
*
|
2005-03-30 |
2012-04-17 |
Decode Genetics Ehf. |
Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
|
US20100216863A1
(en)
*
|
2004-01-30 |
2010-08-26 |
Decode Genetics Ehf. |
Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
|
EP1563837A1
(de)
*
|
2004-02-03 |
2005-08-17 |
Ferrer Internacional, S.A. |
Hypocholesterolämische Zusammensetzungen enthaltend ein Statin und ein Antiflatulenzmittel
|
US20070078109A1
(en)
*
|
2004-02-13 |
2007-04-05 |
David Platt |
Compositions and methods used to treat acne and candida
|
US7501426B2
(en)
*
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
JP4711952B2
(ja)
*
|
2004-02-25 |
2011-06-29 |
興和株式会社 |
Racタンパク質の核内移行促進剤及びそのスクリーニング方法
|
WO2005079847A1
(ja)
|
2004-02-25 |
2005-09-01 |
Kowa Company, Ltd. |
Cdc42タンパク質の核内移行促進剤及びそのスクリーニング方法
|
US7262318B2
(en)
*
|
2004-03-10 |
2007-08-28 |
Pfizer, Inc. |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
CA2460935C
(en)
*
|
2004-03-15 |
2010-05-18 |
Brantford Chemicals Inc. |
An improved preparation of atorvastatin
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
AU2004317570B2
(en)
|
2004-03-17 |
2011-01-06 |
Ranbaxy Laboratories Limited |
Process for the production of atorvastatin calcium in amorphous form
|
EP1732912B1
(de)
*
|
2004-03-30 |
2008-11-12 |
Lupin Ltd. |
Verbessertes verfahren zur herstellung von 4-hydroxypyran-2-onderivaten
|
SI21745A
(sl)
*
|
2004-04-09 |
2005-10-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
|
KR100829268B1
(ko)
*
|
2004-04-16 |
2008-05-13 |
화이자 프로덕츠 인코포레이티드 |
비정질 아토바스타틴 칼슘의 제조 방법
|
EA200601678A1
(ru)
*
|
2004-04-16 |
2007-04-27 |
УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си |
Новые имидазолы
|
EP1744737A2
(de)
*
|
2004-05-03 |
2007-01-24 |
Omega Bio-Pharma (I.P.3) Limited |
Cysteamine zur behandlung von hypercholesterolämie- und diabetes-komplikationen
|
JP2007536373A
(ja)
*
|
2004-05-05 |
2007-12-13 |
ファイザー・プロダクツ・インク |
アトルバスタチンの塩形態
|
JP2008500327A
(ja)
*
|
2004-05-24 |
2008-01-10 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
アトルバスタチンの塩形態
|
EP1748761A4
(de)
*
|
2004-05-27 |
2011-10-12 |
Dexcel Pharma Technologies Ltd |
Lokalisierte kontrollierte absorption von statinen im gastrointestinaltrakt zur erzielung hoher statinspiegel im blut
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
US20050288340A1
(en)
*
|
2004-06-29 |
2005-12-29 |
Pfizer Inc |
Substituted heteroaryl- and phenylsulfamoyl compounds
|
US7534763B2
(en)
|
2004-07-02 |
2009-05-19 |
Bristol-Myers Squibb Company |
Sustained release GLP-1 receptor modulators
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
US20070021346A1
(en)
*
|
2005-05-26 |
2007-01-25 |
Ewing William R |
N-terminally modified GLP-1 receptor modulators
|
US7145040B2
(en)
*
|
2004-07-02 |
2006-12-05 |
Bristol-Myers Squibb Co. |
Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
|
US7786163B2
(en)
*
|
2004-07-12 |
2010-08-31 |
Forest Laboratories Holdings Limited (BM) |
Constrained cyano compounds
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
EP1771455B1
(de)
*
|
2004-07-16 |
2016-05-11 |
LEK Pharmaceuticals d.d. |
Oxidative abbauprodukte von atorvastatin-calcium
|
WO2006011041A2
(en)
|
2004-07-20 |
2006-02-02 |
Warner-Lambert Company Llc |
Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
|
KR100637762B1
(ko)
*
|
2004-07-30 |
2006-10-23 |
주식회사 지니스 |
저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
|
US20110217412A1
(en)
*
|
2004-07-30 |
2011-09-08 |
Jinis Biopharmaceuticals Co. |
Cholesterol lowering supplement and low cholesterol egg produced by using the same
|
EP1773128A2
(de)
*
|
2004-08-02 |
2007-04-18 |
Pro-Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur verbesserung der chemotherapie mit mikrobiellen zytotoxinen
|
CA2576196A1
(en)
*
|
2004-08-06 |
2006-02-16 |
Transform Pharmaceuticals, Inc. |
Novel statin pharmaceutical compositions and related methods of treatment
|
BRPI0513082A
(pt)
*
|
2004-08-06 |
2008-04-22 |
Transform Pharmaceuticals Inc |
formulações de fenofibrato e métodos de tratamento relacionados
|
US20090042979A1
(en)
*
|
2004-08-06 |
2009-02-12 |
Transform Pharmaceuticals Inc. |
Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
|
WO2006026273A2
(en)
*
|
2004-08-25 |
2006-03-09 |
Merck & Co., Inc. |
Method of treating atherosclerosis, dyslipidemias and related conditions
|
WO2006021968A1
(en)
*
|
2004-08-26 |
2006-03-02 |
Biocon Limited |
PROCESS FOR PREPARATION OF 4-FLUORO-α-[2-METHYL-1-OXOPROPYL]Ϝ-OXO-N-β-DIPHENYLBENZENE BUTANE AMIDE
|
CA2578722C
(en)
*
|
2004-08-27 |
2010-02-02 |
Biocon Limited |
Process for atorvastatin calcium amorphous
|
US20080033032A1
(en)
*
|
2004-08-27 |
2008-02-07 |
Sandoz A/S |
Novel Polymorphs Of The Potassium Salt Of Atorvastatin
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
US7674923B2
(en)
*
|
2004-09-28 |
2010-03-09 |
Teva Pharmaceutical Industries Ltd |
Process for preparing forms of atorvastatin calcium substantially free of impurities
|
EP1809759B1
(de)
|
2004-10-06 |
2013-09-11 |
The Brigham And Women's Hospital, Inc. |
Relevanz erzielter niveaus von markern für systemische entzündung nach behandlung
|
US7517991B2
(en)
*
|
2004-10-12 |
2009-04-14 |
Bristol-Myers Squibb Company |
N-sulfonylpiperidine cannabinoid receptor 1 antagonists
|
CA2582087A1
(en)
*
|
2004-10-18 |
2006-04-27 |
Teva Pharmaceutical Industries Ltd. |
Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
|
US7923573B2
(en)
|
2004-10-27 |
2011-04-12 |
Daiichi Sankyo Company, Limited |
Benzene compound having 2 or more substituents
|
US7939675B2
(en)
|
2004-10-28 |
2011-05-10 |
Pfizer, Inc. |
Process for forming amorphous atorvastatin
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
US20090208539A1
(en)
*
|
2004-11-22 |
2009-08-20 |
Adel Penhasi |
Stable atorvastatin formulations
|
CA2588215A1
(en)
*
|
2004-11-22 |
2006-05-26 |
Dexcel Pharma Technologies Ltd. |
Controlled absorption of statins in the intestine
|
AU2005308575A1
(en)
*
|
2004-11-23 |
2006-06-01 |
Warner-Lambert Company Llc |
7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as HMG Co-A reductase inhibitors for the treatment of lipidemia
|
WO2006059224A1
(en)
*
|
2004-12-02 |
2006-06-08 |
Warner-Lambert Company Llc |
Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
|
CA2590860C
(en)
|
2004-12-09 |
2011-05-03 |
Merck & Co., Inc. |
Estrogen receptor modulators
|
US7635699B2
(en)
*
|
2004-12-29 |
2009-12-22 |
Bristol-Myers Squibb Company |
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7589088B2
(en)
*
|
2004-12-29 |
2009-09-15 |
Bristol-Myers Squibb Company |
Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
|
US20080194548A1
(en)
*
|
2005-01-06 |
2008-08-14 |
Forrest Michael J |
Drug Combination Therapy and Pharmaceutical Compositions for Treating Inflammatory Disorders
|
WO2006076598A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
WO2006076597A1
(en)
*
|
2005-01-12 |
2006-07-20 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US7220859B2
(en)
|
2005-01-12 |
2007-05-22 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid receptor modulators
|
US20060160850A1
(en)
*
|
2005-01-18 |
2006-07-20 |
Chongqing Sun |
Bicyclic heterocycles as cannabinoid receptor modulators
|
AP2764A
(en)
*
|
2005-01-31 |
2013-09-30 |
Mylan Lab Inc |
Hydroxylated nebivolol metabolites
|
ES2319461T3
(es)
*
|
2005-02-10 |
2009-05-07 |
Bristol-Myers Squibb Company |
Dihidroquinazolinonas como moduladores de 5ht.
|
WO2006123358A2
(en)
*
|
2005-02-22 |
2006-11-23 |
Sun Pharmaceutical Industries Limited |
Stabilized atorvastatin-containing formulation
|
US20070293535A1
(en)
*
|
2005-02-24 |
2007-12-20 |
Kowa Company, Ltd. |
Nuclear Transfer Promoter for Ddc42 Protein and Method of Screening the Dame
|
CA2498978A1
(en)
*
|
2005-02-28 |
2006-08-28 |
Apotex Pharmachem Inc. |
An improved process for the preparation of atorvastatin and intermediates
|
CA2499047A1
(en)
*
|
2005-03-01 |
2006-09-01 |
Apotex Pharmachem Inc. |
Process for producing atorvastatin hemicalcium
|
JP2008531691A
(ja)
|
2005-03-02 |
2008-08-14 |
メルク エンド カムパニー インコーポレーテッド |
カテプシンk阻害組成物
|
EP1863449A2
(de)
*
|
2005-03-28 |
2007-12-12 |
Dexcel Pharma Technologies Ltd. |
Kontrollierte resorption von statinen im darm
|
GB2424880A
(en)
*
|
2005-04-06 |
2006-10-11 |
Generics |
Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase
|
CZ2007772A3
(cs)
*
|
2005-04-08 |
2008-02-27 |
EGIS GYOGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság |
Nová krystalická polymorfní forma hemivápenaté soli atorvastatinu
|
EP1879881A2
(de)
|
2005-04-14 |
2008-01-23 |
Bristol-Myers Squibb Company |
Inhibitoren der 11-beta-hydroxysteroiddehydrogenase vom typ i
|
WO2006117761A2
(en)
*
|
2005-05-03 |
2006-11-09 |
Ranbaxy Laboratories Limited |
Magnesium salts of hmg-coa reductase inhibitors
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
US7521557B2
(en)
|
2005-05-20 |
2009-04-21 |
Bristol-Myers Squibb Company |
Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
|
US7825139B2
(en)
*
|
2005-05-25 |
2010-11-02 |
Forest Laboratories Holdings Limited (BM) |
Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
|
WO2006125304A1
(en)
*
|
2005-05-25 |
2006-11-30 |
Liponex, Inc. |
Pharmaceutical compositions for treating or preventing coronary artery disease
|
AU2005332300B2
(en)
|
2005-05-31 |
2011-07-07 |
Mylan Laboratories, Inc. |
Compositions comprising nebivolol
|
US7572808B2
(en)
*
|
2005-06-17 |
2009-08-11 |
Bristol-Myers Squibb Company |
Triazolopyridine cannabinoid receptor 1 antagonists
|
US20060287342A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mikkilineni Amarendra B |
Triazolopyrimidine heterocycles as cannabinoid receptor modulators
|
US7629342B2
(en)
*
|
2005-06-17 |
2009-12-08 |
Bristol-Myers Squibb Company |
Azabicyclic heterocycles as cannabinoid receptor modulators
|
US7632837B2
(en)
*
|
2005-06-17 |
2009-12-15 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoid-1 receptor modulators
|
US7452892B2
(en)
*
|
2005-06-17 |
2008-11-18 |
Bristol-Myers Squibb Company |
Triazolopyrimidine cannabinoid receptor 1 antagonists
|
US7317012B2
(en)
*
|
2005-06-17 |
2008-01-08 |
Bristol-Myers Squibb Company |
Bicyclic heterocycles as cannabinoind-1 receptor modulators
|
ES2525217T3
(es)
|
2005-06-27 |
2014-12-19 |
Exelixis Patent Company Llc |
Moduladores de LXR basados en imidazol
|
WO2007004236A2
(en)
|
2005-07-04 |
2007-01-11 |
Ramu Krishnan |
Improved drug or pharmaceutical compounds and a preparation thereof
|
JP5490409B2
(ja)
|
2005-07-11 |
2014-05-14 |
コルトリア・コーポレーション |
スタチンおよびメチルニコチンアミド誘導体を含んでなるリポ蛋白質異常の処置用調剤
|
BRPI0614485A2
(pt)
*
|
2005-07-28 |
2011-03-29 |
Bristol-Myers Squibb Company |
tetrahidro-1h-pirido [4, 3, b] indóis substituìdos como agonistas e antagonistas receptores de serotonina
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20070032665A1
(en)
*
|
2005-08-04 |
2007-02-08 |
Srinivasulu Gudipati |
Preparation of atorvastatin calcium form i
|
CN101500555A
(zh)
*
|
2005-08-04 |
2009-08-05 |
变换药品公司 |
包含非诺贝特和他汀的新型制剂及相关治疗方法
|
BRPI0614280A2
(pt)
|
2005-08-15 |
2009-08-04 |
Arrow Int Ltd |
atorvastatina sódica cristalina e amorfa
|
CA2619486C
(en)
|
2005-08-15 |
2015-05-12 |
Arrow International Limited |
Crystalline and amorphous sodium atorvastatin
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
PE20070335A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
JP2009507822A
(ja)
*
|
2005-09-09 |
2009-02-26 |
ファイザー・サイエンス・アンド・テクノロジー・アイルランド・リミテッド |
アトルバスタチン中間体の調製
|
US20090221839A1
(en)
*
|
2005-09-09 |
2009-09-03 |
Pfizer Inc. |
Preparation of an Atorvastatin Intermediate
|
US20090216029A1
(en)
*
|
2005-09-16 |
2009-08-27 |
Yatendra Kumar |
Process for the production of atorvastatin calcium in amorphous form
|
WO2007035395A2
(en)
*
|
2005-09-16 |
2007-03-29 |
Virginia Commonwealth University Intellectual Property Foundation |
Therapeutic compositions comprising chorionic gonadotropins and hmg coa reductase inhibitors
|
CA2547216A1
(en)
*
|
2005-09-21 |
2007-03-21 |
Renuka D. Reddy |
Process for annealing amorphous atorvastatin
|
US8119358B2
(en)
|
2005-10-11 |
2012-02-21 |
Tethys Bioscience, Inc. |
Diabetes-related biomarkers and methods of use thereof
|
DE102005049293A1
(de)
*
|
2005-10-15 |
2007-04-26 |
Bayer Healthcare Ag |
Kombinationspräparate von Salzen oder o-Acetylsalicylsäure
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
US8618115B2
(en)
|
2005-10-26 |
2013-12-31 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
|
EP1943215A2
(de)
|
2005-10-31 |
2008-07-16 |
Brystol-Myers Squibb Company |
Inhibitoren von dipeptidylpeptidase iv auf pyrrolidinyl-beta-aminoamidbasis und verfahren
|
BRPI0618379A2
(pt)
|
2005-11-08 |
2011-08-30 |
Ranbaxy Lab Ltd |
processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
|
EP1957452B1
(de)
|
2005-11-21 |
2010-05-05 |
Warner-Lambert Company LLC |
Neue formen von [r-(r*,r*)]-2-(4-fluorphenyl)-b,d-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrol-1-heptansäure-magnesium
|
ATE466840T1
(de)
|
2005-11-21 |
2010-05-15 |
Warner Lambert Co |
Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US20070129419A1
(en)
*
|
2005-12-01 |
2007-06-07 |
Christophe Grundschober |
Serotonin transporter (SERT) inhibitors for the treatment of depression and anxiety
|
BRPI0610344A2
(pt)
*
|
2005-12-13 |
2016-11-29 |
Teva Pharma |
forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal
|
US7592461B2
(en)
|
2005-12-21 |
2009-09-22 |
Bristol-Myers Squibb Company |
Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
EP1981849A1
(de)
*
|
2005-12-29 |
2008-10-22 |
LEK Pharmaceuticals D.D. |
Heterocyclische verbindungen
|
AU2006335153B2
(en)
|
2006-01-05 |
2012-03-15 |
Essentialis, Inc. |
Salts of potassium ATP channel openers and uses thereof
|
US20070238669A1
(en)
*
|
2006-01-11 |
2007-10-11 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes related conditions
|
EP1810667A1
(de)
|
2006-01-20 |
2007-07-25 |
KRKA, tovarna zdravil, d.d., Novo mesto |
Pharmazeutische Zusammensetzung enthaltend amorphes Atorvastatin
|
US7553836B2
(en)
*
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
EP1818049A3
(de)
*
|
2006-02-10 |
2008-11-19 |
LifeCycle Pharma A/S |
Stabilisierter Atorvastatin
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2007096751A1
(en)
*
|
2006-02-21 |
2007-08-30 |
Cadila Healthcare Limited |
Process for the preparation of atorvastatin calcium
|
CA2640573A1
(en)
*
|
2006-03-01 |
2007-09-13 |
Michael Pinchasov |
Process for preparing a crystalline form of atorvastatin hemi-calcium
|
US20070238770A1
(en)
*
|
2006-04-05 |
2007-10-11 |
Bristol-Myers Squibb Company |
Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
|
SI22255A
(sl)
*
|
2006-04-14 |
2007-10-31 |
Krka, Tovarna Zdravil, D.D., Novo Mesto |
Novi polimorfi statinovih soli in njihova uporabav farmacevtskih formulacijah
|
PL2010528T3
(pl)
|
2006-04-19 |
2018-03-30 |
Novartis Ag |
6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
|
HUE027872T2
(en)
*
|
2006-05-03 |
2016-11-28 |
Msn Laboratories Private Ltd |
A novel process for statins and their pharmaceutically acceptable salts
|
PE20110235A1
(es)
*
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
NZ600394A
(en)
|
2006-05-04 |
2014-04-30 |
Boehringer Ingelheim Int |
Polymorphs of a dpp-iv enzyme inhibitor
|
US20070265456A1
(en)
*
|
2006-05-09 |
2007-11-15 |
Judith Aronhime |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
US20090082421A1
(en)
*
|
2006-05-11 |
2009-03-26 |
Biocon Limited |
Crystalline Form B4 of Atorvastatin Magnesium and a Process Thereof
|
US20070269503A1
(en)
*
|
2006-05-16 |
2007-11-22 |
James Walter Burgess |
Combinations of HMG CoA reductase inhibitors and negatively charged phospholipids and uses thereof
|
US20100022457A1
(en)
*
|
2006-05-26 |
2010-01-28 |
Bristol-Myers Squibb Company |
Sustained release glp-1 receptor modulators
|
EP2030025A2
(de)
|
2006-06-07 |
2009-03-04 |
Tethys Bioscience, Inc. |
Mit arteriovaskulären ereignissen assoziierte marker und verfahren zu ihrer verwendung
|
US20080096900A1
(en)
|
2006-06-26 |
2008-04-24 |
Amgen Inc. |
Methods for treating atherosclerosis
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
WO2008001499A1
(fr)
|
2006-06-29 |
2008-01-03 |
Kowa Co., Ltd. |
Agent prophylactique et/ou thérapeutique pour le traitement de la polyarthrite rhumatoïde
|
US20080044326A1
(en)
*
|
2006-07-04 |
2008-02-21 |
Esencia Co., Ltd. |
Sterilizer for baby products
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
EP2046119A2
(de)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Behandlung von psychiatrischen störungen
|
US7727978B2
(en)
|
2006-08-24 |
2010-06-01 |
Bristol-Myers Squibb Company |
Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
|
CN101511348B
(zh)
|
2006-08-30 |
2012-04-18 |
国立大学法人九州大学 |
含有包封他汀类之纳米颗粒的药物组合物
|
JP5489333B2
(ja)
|
2006-09-22 |
2014-05-14 |
メルク・シャープ・アンド・ドーム・コーポレーション |
脂肪酸合成阻害剤を用いた治療の方法
|
WO2008042876A2
(en)
|
2006-10-02 |
2008-04-10 |
Codexis, Inc. |
Compositions and methods for producing stereoisomerically pure statins and synthetic intermediates therefor
|
US8404841B2
(en)
*
|
2006-10-09 |
2013-03-26 |
Msn Laboratories Limited |
Process for the preparation of statins and their pharmaceutically acceptable salts thereof
|
US20080118572A1
(en)
*
|
2006-10-10 |
2008-05-22 |
Harold Richard Hellstrom |
Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood
|
EP2079448A2
(de)
*
|
2006-10-10 |
2009-07-22 |
Dexcel Pharma Technologies Ltd. |
Verbesserte freisetzung von statinen im darm
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
US7968577B2
(en)
|
2006-11-01 |
2011-06-28 |
Bristol-Myers Squibb Company |
Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
|
WO2008053312A2
(en)
*
|
2006-11-02 |
2008-05-08 |
Cadila Pharmaceuticals Limited |
Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
|
KR100793321B1
(ko)
*
|
2006-11-29 |
2008-01-11 |
사회복지법인 삼성생명공익재단 |
후각장애 치료 및 예방용 조성물
|
PL2336120T3
(pl)
|
2007-01-10 |
2014-12-31 |
Msd Italia Srl |
Kombinacje zawierające indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy) (PARP)
|
US7834195B2
(en)
*
|
2007-01-24 |
2010-11-16 |
Apotex Pharmachem Inc. |
Atorvastatin calcium propylene glycol solvates
|
KR100878140B1
(ko)
*
|
2007-01-29 |
2009-01-12 |
한미약품 주식회사 |
아토바스타틴의 스트론튬염 또는 이의 수화물, 및 이를포함하는 약학 조성물
|
BRPI0808523A2
(pt)
|
2007-03-01 |
2014-08-19 |
Novartis Vaccines & Diagnostic |
Inibidores de pim cinase e métodos de seu uso
|
KR101012917B1
(ko)
*
|
2007-03-02 |
2011-02-08 |
동아제약주식회사 |
피롤 헵탄산 화합물의 신규한 결정형
|
WO2008112887A1
(en)
*
|
2007-03-13 |
2008-09-18 |
Musc Foundation For Research Development |
Methods of treating juvenile type 1 diabetes mellitus
|
PE20090185A1
(es)
|
2007-03-22 |
2009-02-28 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
WO2008124121A1
(en)
*
|
2007-04-06 |
2008-10-16 |
Scidose, Llc |
Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
|
US20080248115A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
CN101687873A
(zh)
|
2007-04-17 |
2010-03-31 |
百时美施贵宝公司 |
具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
|
DK2147315T3
(da)
|
2007-04-18 |
2013-09-23 |
Tethys Bioscience Inc |
Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
|
PE20090696A1
(es)
*
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
PT2140882E
(pt)
|
2007-04-27 |
2013-09-30 |
Univ Kyushu Nat Univ Corp |
Agente para tratamento de doença pulmonar
|
US8048880B2
(en)
*
|
2007-05-03 |
2011-11-01 |
Anthera Pharmaceuticals, Inc. |
Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
|
US20080280970A1
(en)
*
|
2007-05-08 |
2008-11-13 |
Czarnik Anthony W |
Deuterium-enriched atorvastatin
|
EP2147008A2
(de)
*
|
2007-05-18 |
2010-01-27 |
Bristol-Myers Squibb Company |
Kristalline strukturen von sglt2-hemmern und verfahren zu ihrer herstellung
|
KR20100017866A
(ko)
|
2007-05-21 |
2010-02-16 |
노파르티스 아게 |
Csf-1r 억제제, 조성물 및 사용 방법
|
US8158677B2
(en)
|
2007-06-01 |
2012-04-17 |
The Trustees Of Princeton University |
Treatment of viral infections by modulation of host cell metabolic pathways
|
GB0711250D0
(en)
|
2007-06-12 |
2007-07-18 |
Cbz Chemicals Ltd |
Furanose derivatives
|
US20100190761A1
(en)
|
2007-06-20 |
2010-07-29 |
Anthony Ogawa |
Diphenyl substituted alkanes
|
DE102007028407A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028320A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028406A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
DE102007028319A1
(de)
|
2007-06-20 |
2008-12-24 |
Bayer Healthcare Ag |
Substituierte Oxazolidinone und ihre Verwendung
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
US20090011994A1
(en)
*
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
WO2009013633A2
(en)
*
|
2007-07-20 |
2009-01-29 |
Actavis Group Ptc Ehf |
Amorphous coprecipitates of atorvastatin pharmaceutically acceptable salts
|
NZ597885A
(en)
|
2007-07-26 |
2013-08-30 |
Amgen Inc |
Modified lecithin-cholesterol acyltransferase enzymes
|
EP2173717B9
(de)
*
|
2007-07-27 |
2013-06-26 |
Bristol-Myers Squibb Company |
Neuartige glucokinase-aktivatoren und verfahren zu ihrer verwendung
|
JP2010534644A
(ja)
*
|
2007-07-27 |
2010-11-11 |
シプラ・リミテッド |
医薬組成物およびその製造方法
|
US20110112069A1
(en)
*
|
2007-08-17 |
2011-05-12 |
Boehringer Ingelheim International Gmbh |
Purin derivatives for use in the treatment of fab-related diseases
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
US20090209608A1
(en)
*
|
2007-08-29 |
2009-08-20 |
Protia, Llc |
Deuterium-enriched asenapine
|
KR100921195B1
(ko)
|
2007-10-25 |
2009-10-13 |
주식회사 대웅제약 |
아토르바스타틴의 제조 방법
|
ES2448839T3
(es)
|
2007-11-01 |
2014-03-17 |
Bristol-Myers Squibb Company |
Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
|
WO2009063476A1
(en)
*
|
2007-11-16 |
2009-05-22 |
Biocon Limited |
A crystalline form of atorvastatin hemi magnesium salt and a process thereof
|
US20090163452A1
(en)
*
|
2007-12-20 |
2009-06-25 |
Schwartz Janice B |
Compositions and methods for lowering serum cholesterol
|
MX2010006972A
(es)
|
2007-12-21 |
2010-08-26 |
Ligand Pharm Inc |
Moduladores selectivos de receptores de andrógenos (sarm) y usos de los mismos.
|
CN101205209B
(zh)
*
|
2007-12-25 |
2010-06-02 |
浙江新东港药业股份有限公司 |
一种阿伐他汀中间体的精制方法
|
KR100850558B1
(ko)
*
|
2008-01-02 |
2008-08-06 |
조동옥 |
아토르바스타틴의 효율적인 제조방법
|
NZ600721A
(en)
*
|
2008-01-10 |
2013-03-28 |
Takeda Pharmaceutical |
Capsule formulation
|
MY158798A
(en)
|
2008-01-11 |
2016-11-15 |
Reata Pharmaceuticals Inc |
Synthetic triterpenoids and methods of use in the treatment of disease
|
US20090226515A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Statin compositions
|
US20090226516A1
(en)
*
|
2008-03-04 |
2009-09-10 |
Pharma Pass Ii Llc |
Sartan compositions
|
US20110111026A1
(en)
*
|
2008-03-10 |
2011-05-12 |
Adel Penhasi |
Humidity-resistant drug formulations and methods of preparation thereof
|
KR100980379B1
(ko)
|
2008-04-02 |
2010-09-06 |
주식회사 파마코스텍 |
광학활성을 갖는 5-히드록시-3-옥소헵타노에이트 유도체의제조방법
|
PE20091730A1
(es)
|
2008-04-03 |
2009-12-10 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
EP2130819A3
(de)
*
|
2008-04-10 |
2009-12-23 |
Ranbaxy Laboratories Limited |
Kristalline Formen von Atorvastatin-Magnesium
|
EP2288378A4
(de)
*
|
2008-04-16 |
2011-12-14 |
Univ Utah Res Found |
Pharmakologisches targeting von gefässfehlbildungen
|
EP2285352A2
(de)
*
|
2008-05-13 |
2011-02-23 |
Dr. Reddy's Laboratories Ltd. |
Atorvastatin-zusammensetzungen
|
PE20091928A1
(es)
*
|
2008-05-29 |
2009-12-31 |
Bristol Myers Squibb Co |
Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
|
ES2330184B1
(es)
|
2008-06-03 |
2010-07-05 |
Neuron Biopharma, S.A. |
Uso de estatinas como anticonvulsivantes, antiepilepticos y neuroprotectores.
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
EP2138178A1
(de)
|
2008-06-28 |
2009-12-30 |
Bayer Schering Pharma Aktiengesellschaft |
Oxazolidninone zur Behandlung der chronisch obstruktiven Lungenerkrankung (COPD) und/oder Asthma
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
WO2010019435A2
(en)
*
|
2008-08-14 |
2010-02-18 |
Teva Pharmaceutical Industries Ltd. |
Solid states of atorvastatin potassium
|
NZ604091A
(en)
*
|
2008-08-15 |
2014-08-29 |
Boehringer Ingelheim Int |
Purin derivatives for use in the treatment of fab-related diseases
|
EP2161024A1
(de)
|
2008-09-05 |
2010-03-10 |
Universitätsklinikum Hamburg-Eppendorf |
Kombinationspräparat zur Behandlung von Krebs
|
BRPI0919288A2
(pt)
|
2008-09-10 |
2015-12-15 |
Boehring Ingelheim Internat Gmbh |
teriapia de combinação para tratamento de diabetes e condições relacionadas.
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
EP2382216A1
(de)
|
2008-12-23 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Salzformen einer organischen verbindung
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
EP2387561A4
(de)
|
2009-01-19 |
2012-07-25 |
Msn Lab Ltd |
Verbessertes verfahren zur herstellung von hochreiner (3r,5s)-7-[2-cyclopropyl-4-(4-fluorphenyl) chinolin-3-yl]-3,5-dihydroxy-6(e)-heptensäure und pharmazeutisch akzeptable salze daraus
|
US8115015B2
(en)
*
|
2009-01-26 |
2012-02-14 |
Cadila Healthcare Limited |
Process for the preparation of amorphous atorvastatin calcium
|
WO2010093601A1
(en)
|
2009-02-10 |
2010-08-19 |
Metabasis Therapeutics, Inc. |
Novel sulfonic acid-containing thyromimetics, and methods for their use
|
GB0904102D0
(en)
|
2009-03-10 |
2009-04-22 |
Bradford Pharma Ltd |
Use of atorvastatin lactols as medicaments
|
GB0904100D0
(en)
|
2009-03-10 |
2009-04-22 |
Bradford Pharma Ltd |
Use of rosuvastatin lactols as medicaments
|
GB0904104D0
(en)
|
2009-03-10 |
2009-04-22 |
Bradford Pharma Ltd |
Atorvastatin and rosuvastatin derivatives
|
MX2011009852A
(es)
|
2009-03-27 |
2011-09-29 |
Bristol Myers Squibb Co |
Metodos para prevenir episodios cardiovasculares adversos mayores con inhibidores de dipeptidil peptidasa iv.
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
CN102976996B
(zh)
*
|
2009-05-27 |
2015-08-19 |
峡江和美药业有限公司 |
阿伐他汀半锶盐多晶型物、其制备和作为HMG-CoA酶抑制剂的应用
|
LT2435410T
(lt)
|
2009-05-28 |
2017-04-10 |
Exelixis Patent Company Llc |
Lxr moduliatoriai
|
EP2448564A2
(de)
|
2009-07-02 |
2012-05-09 |
Bilgic Mahmut |
Löslichkeitsverstärkende pharmazeutische formulierung
|
EP2473515A4
(de)
|
2009-09-04 |
2013-11-27 |
Univ Toledo |
Verfahren zur herstellung optisch reiner beta-laktone aus aldehyden und daraus hergestellte zusammensetzungen
|
UA109417C2
(uk)
|
2009-10-14 |
2015-08-25 |
Мерк Шарп Енд Доме Корп. |
ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ
|
CA2780938A1
(en)
|
2009-11-13 |
2011-05-19 |
Bristol-Myers Squibb Company |
Reduced mass metformin formulations
|
LT2498759T
(lt)
|
2009-11-13 |
2018-11-26 |
Astrazeneca Ab |
Greito atpalaidavimo tabletės kompozicijos
|
BR112012011726A2
(pt)
|
2009-11-13 |
2020-05-19 |
Bristol-Myers Squibb Company |
comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
|
KR20230021159A
(ko)
|
2009-11-27 |
2023-02-13 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
AR079336A1
(es)
*
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
JP2011121949A
(ja)
|
2009-12-14 |
2011-06-23 |
Kyoto Univ |
筋萎縮性側索硬化症の予防および治療用医薬組成物
|
EP2526099B1
(de)
|
2010-01-18 |
2016-03-30 |
MSN Laboratories Limited |
Verbessertes verfahren zur herstellung von amid-zwischenprodukten und seine anwendung
|
CZ201039A3
(cs)
|
2010-01-19 |
2011-07-27 |
Zentiva, K. S |
Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme
|
AU2011210508B2
(en)
|
2010-02-01 |
2015-01-29 |
The Hospital For Sick Children |
Remote ischemic conditioning for treatment and prevention of restenosis
|
TWI562775B
(en)
|
2010-03-02 |
2016-12-21 |
Lexicon Pharmaceuticals Inc |
Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
|
SG10201502031XA
(en)
|
2010-03-31 |
2015-05-28 |
Hospital For Sick Children |
Use of remote ischemic conditioning to improve outcome after myocardial infarction
|
KR20130040878A
(ko)
|
2010-04-08 |
2013-04-24 |
더 호스피탈 포 식 칠드런 |
외상성 손상을 위한 원격 허혈 처치의 사용
|
EP2558461B1
(de)
|
2010-04-14 |
2015-12-02 |
Bristol-Myers Squibb Company |
Neuartige glucokinase-aktivatoren und verfahren zu ihrer verwendung
|
US8372877B2
(en)
|
2010-04-16 |
2013-02-12 |
Cumberland Pharmaceuticals |
Stabilized statin formulations
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
IT1400310B1
(it)
|
2010-05-10 |
2013-05-24 |
Menarini Int Operations Lu Sa |
Associazione di inibitori della xantina ossidasi e statine e loro uso.
|
EP2571860A1
(de)
|
2010-05-21 |
2013-03-27 |
Pfizer Inc |
2-phenyl-benzoylamide
|
WO2011152803A1
(en)
|
2010-06-03 |
2011-12-08 |
Mahmut Bilgic |
Water soluble formulation comprising a combination of amlodipine and a statin
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
WO2011161161A1
(en)
|
2010-06-24 |
2011-12-29 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
TR201005326A2
(tr)
|
2010-06-30 |
2012-01-23 |
Bi̇lgi̇ç Mahmut |
Çoklu dozaj formları.
|
RU2596787C2
(ru)
|
2010-07-09 |
2016-09-10 |
БиЭйчВи ФАРМА, ИНК. |
Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
|
KR20120011249A
(ko)
|
2010-07-28 |
2012-02-07 |
주식회사 경보제약 |
아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법
|
EP2601293B1
(de)
|
2010-08-02 |
2017-12-06 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US8883801B2
(en)
|
2010-08-23 |
2014-11-11 |
Merck Sharp & Dohme Corp. |
Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
|
US20130156720A1
(en)
|
2010-08-27 |
2013-06-20 |
Ironwood Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
|
EP2613782B1
(de)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
US9242981B2
(en)
|
2010-09-16 |
2016-01-26 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel ERK inhibitors
|
JPWO2012046772A1
(ja)
|
2010-10-06 |
2014-02-24 |
国立大学法人 東京大学 |
リンパ浮腫予防治療剤
|
WO2012056509A1
(ja)
*
|
2010-10-25 |
2012-05-03 |
興和株式会社 |
医薬組成物
|
EP3327125B1
(de)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna-interferenz-vermittelte inhibition von genexpression unter verwendung kurzer interferierender nukleinsäure (sina)
|
TWI462739B
(zh)
|
2010-11-02 |
2014-12-01 |
Univ Kaohsiung Medical |
Sildenafil-同族物四級銨哌嗪鹽類之製備及醫療用途
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
HU230737B1
(hu)
|
2010-11-16 |
2018-01-29 |
EGIS Gyógyszergyár Nyrt |
Eljárás rosuvastatin só előállítására
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
TWI631963B
(zh)
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
JP6078004B2
(ja)
|
2011-01-20 |
2017-02-08 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
ミネラルコルチコイド受容体拮抗薬
|
CN107899010A
(zh)
|
2011-01-28 |
2018-04-13 |
赛诺菲生物技术公司 |
治疗特定受试者组的方法中使用的针对pcsk9的人抗体
|
EP3009136A1
(de)
|
2011-01-31 |
2016-04-20 |
Cadila Healthcare Limited |
Behandlung von lipodystrophie
|
EP2675440B1
(de)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin-cysteinproteasehemmer
|
JP5705580B2
(ja)
|
2011-02-21 |
2015-04-22 |
公益財団法人微生物化学研究会 |
チオアミド化合物、チオアミド化合物の製造方法、[(4r,6r)−6−アミノエチル−1,3−ジオキサン−4−イル]アセテート誘導体の製造方法、及びアトルバスタチンの製造方法
|
EP2680874A2
(de)
|
2011-03-04 |
2014-01-08 |
Pfizer Inc |
Edn3-ähnliche peptide und ihre verwendung
|
TW201242953A
(en)
|
2011-03-25 |
2012-11-01 |
Bristol Myers Squibb Co |
Imidazole prodrug LXR modulators
|
US9050342B2
(en)
|
2011-03-29 |
2015-06-09 |
Pfizer Inc. |
Beneficial effects of combination therapy on cholesterol
|
US9487506B2
(en)
|
2011-04-13 |
2016-11-08 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
MX2013015272A
(es)
|
2011-07-01 |
2014-04-14 |
Dsm Sinochem Pharm Nl Bv |
Cristales micronizados.
|
NZ618698A
(en)
|
2011-07-15 |
2015-08-28 |
Boehringer Ingelheim Int |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
KR101964031B1
(ko)
|
2011-09-16 |
2019-04-02 |
리제너론 파아마슈티컬스, 인크. |
전구단백질 전환효소 서브틸리신 켁신-9 (PCSK9)의 억제제를 투여함으로써 지질단백질(a)의 농도를 낮추는 방법
|
WO2013055606A1
(en)
|
2011-10-13 |
2013-04-18 |
Merck Sharp & Dohme Corp. |
Mineralocorticoid receptor antagonists
|
US9023865B2
(en)
|
2011-10-27 |
2015-05-05 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
WO2013072770A2
(en)
|
2011-11-15 |
2013-05-23 |
Dr. Reddy's Laboratories Ltd. |
Pharmaceutical formulations comprising atorvastatin and glimepiride
|
KR101466617B1
(ko)
|
2011-11-17 |
2014-11-28 |
한미약품 주식회사 |
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
|
WO2013086443A1
(en)
|
2011-12-08 |
2013-06-13 |
Amgen Inc. |
Agonistic human lcat antigen binding proteins and their use in therapy
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
BR112014027047A2
(pt)
|
2012-04-30 |
2017-06-27 |
Hoffmann La Roche |
nova formulação
|
EP3453762B1
(de)
|
2012-05-02 |
2021-04-21 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
CN104684932B
(zh)
|
2012-05-10 |
2019-03-12 |
拜耳药业股份公司 |
能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途
|
KR102136431B1
(ko)
|
2012-05-11 |
2020-07-21 |
싱크로니시티 파마, 인크. |
크립토크롬 조절제로서의 카르바졸-함유 술폰아미드
|
US20130303462A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
MX2014014830A
(es)
|
2012-06-15 |
2015-05-11 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso.
|
WO2014022195A1
(en)
|
2012-08-01 |
2014-02-06 |
Tavakoli Zahra |
Free flowing, frozen compositions comprising a therapeutic agent
|
CA2882950A1
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
CA2891773C
(en)
|
2012-11-20 |
2021-01-19 |
Lexicon Pharmaceuticals, Inc. |
Inhibitors of sodium glucose cotransporter 1
|
BR112015012295A8
(pt)
|
2012-11-28 |
2023-03-14 |
Merck Sharp & Dohme |
Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
|
CN103012240B
(zh)
*
|
2012-12-11 |
2015-05-27 |
保定市龙瑞药物技术有限责任公司 |
一种阿托伐他汀钙的制备方法
|
CN105073746B
(zh)
|
2012-12-20 |
2017-03-22 |
默沙东公司 |
作为hdm2抑制剂的取代的咪唑并吡啶
|
CN103121964A
(zh)
*
|
2013-01-17 |
2013-05-29 |
复旦大学 |
一种制备阿托伐他汀钙关键中间体的方法
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
CN105209039B
(zh)
|
2013-03-15 |
2018-06-22 |
百时美施贵宝公司 |
Lxr调节剂
|
KR101951075B1
(ko)
|
2013-03-21 |
2019-02-21 |
유프락시아 파마수티컬스 유에스에이 엘엘씨 |
주입가능한 서방성 방출 조성물 및 관절 내 염증 및 이와 관련된 통증을 치료하기 위해 이를 사용하는 방법
|
SG11201507496UA
(en)
|
2013-04-17 |
2015-11-27 |
Pfizer |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
AP2015008674A0
(en)
|
2013-04-22 |
2015-08-31 |
Cadila Healthcare Ltd |
A novel composition for nonalcoholic fatty liver disease (NAFLD)
|
US10111953B2
(en)
|
2013-05-30 |
2018-10-30 |
Regeneron Pharmaceuticals, Inc. |
Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
|
ES2889916T3
(es)
|
2013-05-30 |
2022-01-14 |
Cadila Healthcare Ltd |
Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas
|
KR20160024906A
(ko)
|
2013-06-07 |
2016-03-07 |
사노피 바이오테크놀로지 |
Pcsk9의 억제제를 투여함에 의한 죽상경화증의 억제 방법
|
TW201513857A
(zh)
|
2013-07-05 |
2015-04-16 |
Cadila Healthcare Ltd |
協同性組成物
|
IN2013MU02470A
(de)
|
2013-07-25 |
2015-06-26 |
Cadila Healthcare Ltd |
|
WO2015027021A1
(en)
|
2013-08-22 |
2015-02-26 |
Bristol-Myers Squibb Company |
Imide and acylurea derivatives as modulators of the glucocorticoid receptor
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
WO2015033357A2
(en)
|
2013-09-06 |
2015-03-12 |
Cadila Healthcare Limited |
An improved process for the preparation of pyrrole derivatives
|
JP6454335B2
(ja)
|
2013-10-08 |
2019-01-16 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
カテプシンシステインプロテアーゼ阻害剤
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
AU2014348765A1
(en)
|
2013-11-12 |
2016-06-09 |
Regeneron Pharmaceuticals, Inc. |
Dosing regimens for use with PCSK9 inhibitors
|
CN105111123A
(zh)
*
|
2013-11-25 |
2015-12-02 |
李兴惠 |
阿托伐他汀钙及组合物
|
JP6536871B2
(ja)
|
2013-12-02 |
2019-07-03 |
国立大学法人京都大学 |
Fgfr3病の予防および治療剤ならびにそのスクリーニング方法
|
EP3094323A4
(de)
|
2014-01-17 |
2017-10-11 |
Ligand Pharmaceuticals Incorporated |
Verfahren und zusammensetzungen zur modulierung von hormonspiegeln
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|
TWI690521B
(zh)
|
2014-04-07 |
2020-04-11 |
美商同步製藥公司 |
作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
|
RU2016146826A
(ru)
|
2014-05-30 |
2018-07-04 |
Пфайзер Инк. |
Производные карбонитрилов как селективные модуляторы андрогенового рецептора
|
WO2016011256A1
(en)
|
2014-07-16 |
2016-01-21 |
Sanofi Biotechnology |
METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (heFH)
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
WO2016044021A1
(en)
|
2014-09-15 |
2016-03-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Targeting aneurysm disease by modulating phagocytosis pathways
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
WO2016138306A1
(en)
|
2015-02-27 |
2016-09-01 |
The Board Of Trustees Of The Leland Stanford Junior University |
Combination therapy for treatment of coronary artery disease
|
SG11201708323SA
(en)
|
2015-04-30 |
2017-11-29 |
Harvard College |
Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
|
MA42657A
(fr)
|
2015-08-18 |
2018-06-27 |
Regeneron Pharma |
Anticorps inhibiteurs anti-pcsk9 destinés au traitement des patients atteints d'hyperlipidémie subissant une aphérèse de lipoprotéines
|
FR3040303B1
(fr)
*
|
2015-08-27 |
2019-04-05 |
Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger |
Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
|
WO2017064635A2
(en)
|
2015-10-14 |
2017-04-20 |
Cadila Healthcare Limited |
Pyrrole compound, compositions and process for preparation thereof
|
CA3003159A1
(en)
|
2015-10-27 |
2017-05-04 |
Eupraxia Pharmaceuticals Inc. |
Sustained release formulations of local anesthetics
|
JP2019517542A
(ja)
|
2016-06-10 |
2019-06-24 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
リナグリプチンおよびメトホルミンの組合せ
|
ES2894261T3
(es)
|
2016-12-09 |
2022-02-14 |
Cadila Healthcare Ltd |
Tratamiento de la colangitis biliar primaria
|
EP3706742B1
(de)
|
2017-11-08 |
2023-03-15 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
US20210290598A1
(en)
|
2018-05-08 |
2021-09-23 |
National University Corporation Okayama University |
Medicament useful for cardiovascular disease
|
EP3824912A4
(de)
|
2018-07-19 |
2022-04-20 |
Kyoto University |
Aus pluripotenten stammzellen abgeleiteter plattenförmiger knorpel und verfahren zur herstellung von plattenförmigen knorpeln
|
EP3833668A4
(de)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
Prmt5-inhibitoren
|
EP3833667B1
(de)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
BR112021004839A2
(pt)
|
2018-09-26 |
2021-06-08 |
Lexicon Pharmaceuticals, Inc. |
formas cristalinas de n-(1-((2-(dimetilamino)etil)amino)-2-metil-1-oxopropan-2-il)-4-(4-(2-metil-5-((2s,3r,4r,5s,6r)-3,4,5-triidróxi-6-(metiltio)tetraidro-2h-piran-2-il)benzil)fenil)butanamida e métodos de sua síntese
|
WO2020130147A1
(ja)
|
2018-12-21 |
2020-06-25 |
国立大学法人京都大学 |
ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
|
CN113574055A
(zh)
|
2019-01-18 |
2021-10-29 |
阿斯利康(瑞典)有限公司 |
Pcsk9抑制剂及其使用方法
|
KR20210144657A
(ko)
|
2019-03-13 |
2021-11-30 |
고쿠리츠다이가쿠호진 하마마츠이카다이가쿠 |
대동맥류의 치료용 의약 조성물
|
MX2021014552A
(es)
|
2019-05-27 |
2022-02-11 |
Immatics Us Inc |
Vectores viricos y uso de los mismos en terapias celulares adoptivas.
|
AU2020408148A1
(en)
|
2019-12-17 |
2022-06-16 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
JPWO2021167088A1
(de)
|
2020-02-21 |
2021-08-26 |
|
|
DE102020111571A1
(de)
|
2020-03-11 |
2021-09-16 |
Immatics US, Inc. |
Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
|
WO2022023206A1
(en)
|
2020-07-27 |
2022-02-03 |
Krka, D.D., Novo Mesto |
Bilayer tablet comprising ezetimibe and atorvastatin
|
TW202227616A
(zh)
|
2020-08-21 |
2022-07-16 |
美商英麥提克斯股份有限公司 |
分離cd8+選擇t細胞的方法
|
WO2022071787A1
(es)
|
2020-09-29 |
2022-04-07 |
Laboratorios Silanes S.A. De C.V. |
Combinaciones farmacéuticas de estatinas y fibratos para el tratamiento y prevención de hiperlipidemias y enfermedades cardiovasculares
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|